per-chart, page-985

So their terrible 14c target is based on their assumpyions we will raise capital after results. Yet they go on to say any any data warranting further research will likely get US partner interest as theres nothing much happening re competition with solid efficacy. We have cash runway well into first half 25cy.

They also expect we'll need a third trial for approval but then talk of low fda approval bars giving sarepta examples, saying lobby groups there have a big influence and if our results were awesome approval is likely. They dont mention the word partial approval which I assume is where we will land.

id love to know their price target if they assume partnership and partial approval.